Progress in targeted therapy for brain metastasis from non-small-cell lung cancer positive for ALK gene fusion
10.3969/j.issn.1000-8179.2020.02.167
- Author:
Qiang YIN
1
Author Information
1. Department of Neurosurgery and Neuro-Oncology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin Key Laboratory of Cancer Prevention and Therapy
- Publication Type:Journal Article
- Keywords:
Anaplastic lymphoma kinase;
Brain metastasis;
Non-small cell lung cancer;
Targeted therapy;
Tyrosine kinase inhibitors
- From:
Chinese Journal of Clinical Oncology
2020;47(2):95-98
- CountryChina
- Language:Chinese
-
Abstract:
The incidence of anaplastic lymphoma kinase (ALK) gene fusion in non-small-cell lung cancer (NSCLC) is approximately 2%-7%. In cases of lung cancer with this gene mutation, the probability of brain metastasis, which seriously affects quality of life and shortens survival time, is higher. In recent years, survival time has significantly increased among ALK gene fusion-positive NSCLC patients with brain metastasis owing to continuous advances in the development of ALK-tyrosine kinase inhibitors (TKIs). This paper reviews the progress in the research on ALK-TKI use in the treatment of brain metastasis from NSCLC.
